Document is current

Article History

Received: 10 December 2020

Accepted: 13 February 2021

First Online: 22 March 2021

Declarations

:

: CHP-NY-ESO-1 was supplied by ImmunoFrontier Inc. (Osaka, Japan). Hiroshi Shiku is a stockholder of ImmunoFrontier Inc. Shinichi Kageyama, Yoshihiro Miyahara, and Hiroshi Shiku received research funds from ImmunoFrontier Inc. The other authors declare that they have no conflicts of interest.

: All procedures performed in our studies involving human participants were conducted in accordance with Japanese Ethical Guidelines for Clinical Research, Japanese Guidelines for Medical and Health Research Involving Human Subjects, and the Helsinki declaration. The Institutional Review Board reviewed and approved the protocol and the informed consent documents and their amendments before use (Kyoto Prefectural University of Medicine approval number RBMR-C-941–2). All animal experiments were conducted in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions and approved by Mie University (approval number 24–14).

: Female BALB/c mice aged 6–10 weeks were purchased from Japan SLC, Inc. (Shizuoka, Japan).

: The CT26 cell line was purchased from the American Type Culture Collection (Virginia, USA). A human NY-ESO-1 transfected CT26 cell line was established as described previously [].

: Written informed consent to participate in the study and for the use of clinical data for research and publication was obtained from all patients included in the studies: Kyoto Prefectural University of Medicine approval number: RBMR-C-941–2.